22227-59-4

Basic information

• Product Name: 2-chloro-3-nitro-5-(trifluoromethyl)benzoic acid
• Synonyms: 2-chloro-3-nitro-5-(trifluoromethyl)benzoic acid;2-Chloro-3-nitro-5-(trifluoromethyl)
• CAS NO: 22227-59-4
• Molecular Formula: C₈H₃ClF₃NO₄
• Molecular Weight: 269.5619296
• Mol File: 22227-59-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 329.836 °C at 760 mmHg
• Flash Point: 153.28 °C
• Appearance: /
• Density: 1.693 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.50±0.20(Predicted)
• CAS DataBase Reference: 2-chloro-3-nitro-5-(trifluoromethyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-3-nitro-5-(trifluoromethyl)benzoic acid(22227-59-4)
• EPA Substance Registry System: 2-chloro-3-nitro-5-(trifluoromethyl)benzoic acid(22227-59-4)

Safety Data

• Hazardous Substances Data: 22227-59-4(Hazardous Substances Data)

Usage

General Description

2-chloro-3-nitro-5-(trifluoromethyl)benzoic acid is a chemical compound that belongs to the class of benzoic acids. It is characterized by the presence of a chloro, nitro, and trifluoromethyl group on the benzene ring. 2-chloro-3-nitro-5-(trifluoromethyl)benzoic acid is used in the synthesis of various pharmaceuticals and agrochemicals due to its unique chemical properties. It is also used as a building block in organic chemistry for the creation of more complex molecules. Additionally, it has been studied for its potential applications in the field of medicinal chemistry and drug development. Overall, 2-chloro-3-nitro-5-(trifluoromethyl)benzoic acid is a versatile compound with a range of potential uses in different industries.

InChI:InChI=1S/C8H3ClF3NO4/c9-6-4(7(14)15)1-3(8(10,11)12)2-5(6)13(16)17/h1-2H,(H,14,15)

Upstream product

• 657-06-7 2-chloro-5-trifluoromethylbenzoic acid 
• 98-56-6 4-chlorobenzotrifluoride 

Downstream Products

• 87033-30-5 2-chloro-3-nitro-5-(trifluoromethyl)benzoyl chloride 
• 22227-60-7 2-amino 3-nitro-5-trifluoromethylbenzoic acid 
• 22227-47-0 2-chloro-3-nitro-5-(trifluoromethyl)benzamide 
• 1383531-32-5 TK₄₅₄₇-070E 
• 1396842-98-0 2-(4-phenylpiperidin-1-yl)-8-nitro-6-(trifluoro-methyl)-4H-benzo[e][1,3]thiazin-4-one 
• 1427469-45-1 2-(4-(4-chlorophenyl)piperidin-1-yl)-8-nitro-6-(tri-fluoromethyl)-4H-benzo[e][1,3]thiazin-4-one 
• 1427469-48-4 2-(4-(3,4-difluorophenyl)piperidin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one 
• 957217-65-1 BTZ043 
• 1449698-48-9 2-chloro-3-nitro-5-(trifluoromethyl)benzoyl isothiocyanate 
• 910123-03-4 2,3-diamino-5-trifluoromethylbenzoic acid 

Relevant articles and documents

8-cyanobenzothiazinone analogs with potent antitubercular activity

8-Nitrobenzothiazinones (BTZs) exemplified by macozinone are a new class of antitubercular agents with exceptionally potent activity. The aryl nitro group has been considered indispensable for activity since this is bioactivated within mycobacteria by the flavoenzyme DprE1 to a reactive nitroso metabolite that covalently labels Cys387. However, the aryl nitro group is a potential liability with regards to safety, stability, and resistance. In this paper, we introduced a nitrile as a bioisosteric replacement of the nitro group, which we hypothesize can maintain a similar covalent mechanism of inhibition, but mitigate against the aforementioned concerns. 8-cyanobenzothiazinone 1d displayed potent antitubercular activity with an MIC of 130 nM and had an improved volume of distribution in mice that increased the intrinsic half-life by twofold compared to macozinone. Analysis of the C-2 substituent of 1d revealed similar structure–activity relationships as observed for macozinone. Overall, the results confirm the 8-nitro group of benzothiazinones can be successfully replaced with a nitrile to retain useful activity and favorable pharmacokinetic properties. [Figure not available: see fulltext.].

Benzoxazinone derivatives and their use as antibacterial agents

The invention discloses benzoxazinone derivatives, a synthesis method and applications thereof. The derivatives can be used as an antibacterial agent for treating infectious diseases caused by bacteria, especially tuberculosis (TB) caused by mycobacterium. Specifically, the invention relates to compounds represented by the formula (I), pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the provided compounds; wherein the R1 to R4 are defined in the description. The invention aim to prepare novel compounds capable of inhibiting the mycobacterium activity, the compounds can be used as a potential novel drug for treating infectious diseases caused by bacteria, moreover, the compounds can be used to treat or prevent tuberculosis (TB) caused by mycobacterium, at the same time the problems related with drug resistance can be solved, and the drug metabolism property can be improved on the basis that the mycobacterium tuberculosis resistant activity is not influenced.

Benzothiazinone compounds and their use as anti-tuberculosis agents

Novel benzothiazinone derivatives of formula (I) or a pharmaceutically acceptable salt or solvate thereof have been found to be effective against Mycobacterium tuberculosis strains and may thus be useful in the treatment of tuberculosis